In a clinical trial landscape so dependent on optimization and efficiency, unbalanced distribution of product isn’t something trial sites can afford. Yet, waste remains an accepted part of running clinical trials.
Considering the most conservative estimates, investigational medical product (IMP) waste accounts for many billions of euros each year – a total that is multiplied several times over for cell and gene therapy, radiotherapy, and other complex trial types. Even labour waste negatively impacts the bottom line, with manual user assessments and expedited shipments adding considerable budget impact to each trial.
A solution, while still imperfect, comes in the form of leveraging more-advanced track and trace technologies in conjunction with innovative capabilities found in their randomization and trial supply management (RTSM) platforms. These systems provide the technology to support management of inventory within and across studies.